|Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial|
SA Wells Jr, BG Robinson, RF Gagel, H Dralle, JA Fagin, M Santoro, ...
Journal of clinical oncology 30 (2), 134, 2012
|ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases|
F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ...
Cancer research 62 (24), 7284-7290, 2002
|ATM and ATR as therapeutic targets in cancer|
AM Weber, AJ Ryan
Pharmacology & therapeutics 149, 124-138, 2015
|Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA|
AJ Ryan, S Squires, HL Strutt, RT Johnson
Nucleic acids research 19 (12), 3295-3300, 1991
|Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models|
DC Blakey, FR Westwood, M Walker, GD Hughes, PD Davis, SE Ashton, ...
Clinical cancer research 8 (6), 1974-1983, 2002
|Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers|
NR Smith, D Baker, NH James, K Ratcliffe, M Jenkins, SE Ashton, ...
Clinical Cancer Research 16 (14), 3548-3561, 2010
|Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors|
F Carlomagno, T Guida, S Anaganti, G Vecchio, A Fusco, AJ Ryan, ...
Oncogene 23 (36), 6056-6063, 2004
|Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells …|
P Beaudry, J Force, GN Naumov, A Wang, CH Baker, A Ryan, S Soker, ...
Clinical Cancer Research 11 (9), 3514-3522, 2005
|ZD6474–a novel inhibitor of VEGFR and EGFR tyrosine kinase activity|
AJ Ryan, SR Wedge
British journal of cancer 92 (1), S6-S13, 2005
|Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126|
JL Evelhoch, PM LoRusso, Z He, Z DelProposto, L Polin, TH Corbett, ...
Clinical Cancer Research 10 (11), 3650-3657, 2004
|Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis|
RS Herbst, JV Heymach, MS O’Reilly, A Onn, AJ Ryan
Expert opinion on investigational drugs 16 (2), 239-249, 2007
|Vascular endothelial growth factor receptor-1 contributes to resistance to anti–epidermal growth factor receptor drugs in human cancer cells|
R Bianco, R Rosa, V Damiano, G Daniele, T Gelardi, S Garofalo, V Tarallo, ...
Clinical Cancer Research 14 (16), 5069-5080, 2008
|ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits …|
MF McCarty, J Wey, O Stoeltzing, W Liu, F Fan, C Bucana, PF Mansfield, ...
Molecular cancer therapeutics 3 (9), 1041-1048, 2004
|Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation|
SX Pfister, E Markkanen, Y Jiang, S Sarkar, M Woodcock, G Orlando, ...
Cancer cell 28 (5), 557-568, 2015
|ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma|
M Vidal, S Wells, A Ryan, R Cagan
Cancer research 65 (9), 3538-3541, 2005
|Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice|
MV Yezhelyev, G Koehl, M Guba, T Brabletz, KW Jauch, A Ryan, A Barge, ...
Clinical Cancer Research 10 (23), 8028-8036, 2004
|Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non–small-cell lung cancer|
EO Hanrahan, HY Lin, ES Kim, S Yan, DZ Du, KS McKee, HT Tran, JJ Lee, ...
Journal of Clinical Oncology 28 (2), 193, 2010
|Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging|
SP Robinson, DJO McIntyre, D Checkley, JJ Tessier, FA Howe, ...
British journal of cancer 88 (10), 1592-1597, 2003
|Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma|
PR Wachsberger, R Burd, N Marero, C Daskalakis, A Ryan, P McCue, ...
Clinical Cancer Research 11 (2), 835-842, 2005
|ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system …|
JN Rich, S Sathornsumetee, ST Keir, MW Kieran, A Laforme, A Kaipainen, ...
Clinical Cancer Research 11 (22), 8145-8157, 2005